Predicting the in vivo mechanism of action for drug leads using NMR metabolomics

Steven Halouska, Robert J. Fenton, Raúl G. Barletta, Robert Powers

Research output: Contribution to journalArticle

45 Scopus citations

Abstract

New strategies are needed to circumvent increasing outbreaks of resistant strains of pathogens and to expand the dwindling supply of effective antimicrobials. A common impediment to drug development is the lack of an easy approach to determine the in vivo mechanism of action and efficacy of novel drug leads. Toward this end, we describe an unbiased approach to predict in vivo mechanisms of action from NMR metabolomics data. Mycobacterium smegmatis, a non-pathogenic model organism for Mycobacterium tuberculosis, was treated with 12 known drugs and 3 chemical leads identified from a cell-based assay. NMR analysis of drug-induced changes to the M. smegmatis metabolome resulted in distinct clustering patterns correlating with in vivo drug activity. The clustering of novel chemical leads relative to known drugs provides a mean to identify a protein target or predict in vivo activity.

Original languageEnglish (US)
Pages (from-to)166-171
Number of pages6
JournalACS chemical biology
Volume7
Issue number1
DOIs
StatePublished - Jan 20 2012

ASJC Scopus subject areas

  • Biochemistry
  • Molecular Medicine

Fingerprint Dive into the research topics of 'Predicting the in vivo mechanism of action for drug leads using NMR metabolomics'. Together they form a unique fingerprint.

  • Cite this